Developer docs
API playgroundTry for free, no card

Search company profiles

Syndicate Bio

Full company profile

uuid0005isf

Namestring
Syndicate Bio
Legal namestring
Syndicate Bio
Websiteurl
syndicate.bio
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Syndicate Bio is a privately held genomics and precision medicine company founded in 2023 by Abasi Ene-Obong (formerly of 54gene) and operating dual hubs in Newark, Delaware, USA and Lagos, Nigeria. The company operates two go-to-market platforms: Direct by Syndicate Bio, a direct-to-consumer health portal offering an 18-product genetic testing catalog including non-invasive prenatal testing (NIPT), hereditary cancer panels (23-gene to ~300-gene tiers), the OncoMap130 solid tumor and OncoMap90 myeloid oncology panels, pharmacogenomics, and wellness testing, all priced in Nigerian Naira (₦350,000–₦1,500,000); and the Precision54 Clinical Hub, a B2B platform connecting pharmaceutical and biotechnology companies to pre-qualified clinical research sites across Africa for collaborative precision medicine studies.

Underlying technology is next-generation sequencing (NGS) combined with AI/ML analytics applied across multi-omics disciplines (genomics, proteomics, metabolomics, bioinformatics). Syndicate Bio operates an ISO 9001:2015- and ISO 15189:2022-compliant laboratory and positions itself around the genetic diversity of African populations, including Africa-prevalent conditions such as sickle cell disease, thalassemia, G6PD deficiency, and hereditary amyloidosis. Revenue is generated through one-time per-test fees from consumers and healthcare providers (with provider pricing approximately 5% below DTC rates) plus professional-services revenue from pharma/biotech research collaborations. The company's October 2025 Cancer Genome Nigeria Study with NICRAT — analyzing 442 variants across 41 genes in 50 tumors and identifying distinctive ALK and FGFR4 enrichments — establishes its foundational proprietary dataset.

Short descriptiontext

Syndicate Bio is a genomics and precision medicine company that sells clinical-grade genetic testing directly to Nigerian consumers and healthcare providers through its Direct platform, and operates the Precision54 Clinical Hub to connect pharma and biotech partners to African clinical research sites.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLagos, Nigeria
HQ citystring
Lagos
HQ countrystring
Nigeria
HQ regionstring
Africa
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
genetic testing services, clinical genomics platform, precision medicine solutions, cancer genomic profiling, non-invasive prenatal testing
Industry4 codes
PRIMARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAFAMAH
Genetic & Prenatal Testing Laboratories
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
NAICS code4 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories6215
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code3 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Commercial Physical & Biological Research8731
Product category
Genetic Testing & Genomic Diagnostics
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Direct-to-Consumer Genetic Testing
TypeOne Time License
Description

Individual consumers purchase genomic tests directly through the Direct platform, including NIPT, hereditary cancer panels, pharmacogenomics, and wellness tests. Tests are priced at various tiers with provider and consumer pricing options.

direct.syndicate.bio
2Healthcare Provider Testing Services
TypeOne Time License
Description

Oncologists, hospitals, and clinics order tests for patients, receiving clinical-grade reports with actionable guidance. Pricing differs from direct consumer rates (approximately 5% lower for providers).

direct.syndicate.bio
3Pharma/Biotech Research Partnerships
TypeProfessional Services
Description

Collaborative data projects, clinical studies, and sponsored testing for pharmaceutical and biotech companies through the Precision54 Clinical Hub. Enables pharma partners to access African genetic diversity for drug discovery and development.

syndicate.bio
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components1 value
Technology or R&D
Pricing details15 tiers
1NIPT Gender - Basic gender determination test
ModelUnit PricingBilling cadencePay-as-you-go
Notes

₦350,010 (Direct-to-Consumer)

direct.syndicate.bio
2NIPT Basic - Screens for Trisomy 21, 18, 13
ModelUnit PricingBilling cadencePay-as-you-go
Notes

₦350,000 (Direct-to-Consumer)

direct.syndicate.bio
3NIPT Standard - Adds sex chromosome aneuploidies and 19 autosomal aneuploidies
ModelUnit PricingBilling cadencePay-as-you-go
Notes

₦500,000 (Direct-to-Consumer)

direct.syndicate.bio
4NIPT Plus - Most comprehensive NIPT with 60+ microdeletion syndromes
ModelUnit PricingBilling cadencePay-as-you-go
Notes

₦800,000 (Direct-to-Consumer)

direct.syndicate.bio
5Hereditary Conditions Test - 90+ genes for inherited conditions
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Pricing not publicly disclosed

direct.syndicate.bio
6Health & Wellness Test - 80+ wellness-related genes
ModelUnit PricingBilling cadencePay-as-you-go
Notes

₦450,000 (Direct-to-Consumer)

direct.syndicate.bio
7Pharmacogenomics Test - Drug response genes
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Pricing not publicly disclosed

direct.syndicate.bio
8Hereditary Breast & Ovarian Cancer Test - 50 genes
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Pricing not publicly disclosed

direct.syndicate.bio
9Hereditary Prostate Cancer Test - 23 genes
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Pricing not publicly disclosed

direct.syndicate.bio
10Hereditary Pancreatic Cancer Test - 32 genes
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Pricing not publicly disclosed

direct.syndicate.bio
11Hereditary Colorectal Cancer Test - 44 genes
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Pricing not publicly disclosed

direct.syndicate.bio
12OncoMap130 - 130 genes for solid tumors with pharmacogenetics
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Pricing not publicly disclosed

direct.syndicate.bio
13OncoMap90 - 90 genes for myeloid malignancies
ModelUnit PricingBilling cadencePay-as-you-go
Notes

₦900,000 (Direct-to-Consumer), ₦855,000 (Provider)

direct.syndicate.bio
14Comprehensive Hereditary Cancer Test - ~300 genes
ModelUnit PricingBilling cadencePay-as-you-go
Notes

₦750,000 (Direct-to-Consumer), ₦712,500 (Provider)

direct.syndicate.bio
15Complete Genetic Health Package - All three flagship panels combined
ModelUnit Pricing
Notes

₦1,500,000 (Direct-to-Consumer), ₦1,425,000 (Provider). Saves ₦450,000 vs. ordering separately.

direct.syndicate.bio
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Brand1 of 2 records shown
1Precision54
Description

Clinical hub and network for accessing cutting-edge research and pre-qualified clinical trial sites in Africa.

direct.syndicate.bio
+1 more record
Core offering1 text field

Syndicate Bio sells clinical-grade genetic testing services — including NIPT, hereditary cancer panels, hereditary conditions tests, pharmacogenomics, wellness tests, and oncology tumor profiling (OncoMap130, OncoMap90) — through its Direct by Syndicate Bio consumer portal and through healthcare provider channels. The company also operates the Precision54 Clinical Hub, a B2B research network platform enabling pharmaceutical and biotech companies to run precision medicine studies and access pre-qualified clinical sites across Africa. All products are anchored in African-population genomic data and ISO-certified laboratory quality standards.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 442 variants analyzed across 50 tumors and 41 genes in first national Nigerian cancer genomics study
+4 more records
Product overview1 text field

Syndicate Bio is a global genomics and precision medicine company offering a comprehensive portfolio of genetic testing products through its Direct by Syndicate Bio portal. The core offering includes clinical genetic tests organized into three flagship categories: Hereditary Conditions Tests (90+ genes for blood, heart, neurological, metabolic conditions), Hereditary Cancer Tests (ranging from focused 23-50 gene panels to comprehensive ~300 gene panels), and Health & Wellness Tests (80+ genes). The company also provides specialized oncology solutions including OncoMap130 (solid tumor profiling) and OncoMap90 (myeloid cancer panel), as well as Non-Invasive Prenatal Testing (NIPT) with four tiers from gender-only to Plus with microdeletion screening. The Precision54 Clinical Hub provides pharmaceutical and biotech partners with access to pre-qualified research sites across Africa. All tests are designed with African genetic diversity in mind, including variants common in Nigerian and broader African populations.

Product and service18 records
1Direct by Syndicate Bio
CategoryConsumer health portal / direct-to-consumer testing platform
Description

Personal health portal that allows individuals to order genetic tests online, view results securely, and access optional genetic counseling and the Second Opinion Service. Targets health-conscious consumers in Africa seeking direct access to clinical-grade genomic testing.

2Precision54 Clinical Hub
CategoryClinical research network / B2B platform
Description

B2B research network platform connecting pharmaceutical and biotechnology companies with pre-qualified clinical research sites across Africa. Enables collaborative clinical studies, sponsored testing, and data projects with faster study startup times, giving pharma partners access to African genetic diversity for drug discovery and precision medicine research.

3NIPT (Non-Invasive Prenatal Test)
CategoryPrenatal genetic screening
Description

Non-invasive prenatal test analyzing fetal DNA from maternal blood to screen for chromosomal conditions including Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18), and Patau syndrome (Trisomy 13). Performed from 10 weeks of pregnancy with no miscarriage risk. Targets expectant parents seeking safe prenatal screening.

4NIPT Gender
CategoryPrenatal genetic screening
Description

Entry-level non-invasive prenatal test providing accurate fetal gender determination and fetal fraction estimation from 10 weeks of pregnancy. Priced at ₦350,010 direct-to-consumer.

5NIPT Basic
CategoryPrenatal genetic screening
Description

Basic NIPT screening for Trisomy 21 (Down syndrome), Trisomy 18 (Edwards syndrome), and Trisomy 13 (Patau syndrome) with gender determination from 10 weeks of pregnancy. Priced at ₦350,000 direct-to-consumer.

6NIPT Standard
CategoryPrenatal genetic screening
Description

Comprehensive NIPT screening expanding coverage beyond NIPT Basic to include 6 sex chromosome aneuploidies, 19 additional autosomal aneuploidies, and fetal fraction estimation. Priced at ₦500,000 direct-to-consumer.

7NIPT Plus
CategoryPrenatal genetic screening
Description

Most comprehensive NIPT option covering all Standard features plus 60+ microdeletion and duplication syndromes including Jacobsen syndrome and DiGeorge syndrome. Priced at ₦800,000 direct-to-consumer.

8Hereditary Conditions Test
CategoryHereditary conditions diagnostic test
Description

Clinical-grade genetic test screening 90+ genes for inherited conditions including sickle cell disease, G6PD deficiency, thalassemia, hereditary amyloidosis, and other blood, heart, nerve, immune, metabolic, and eye conditions. Targets individuals and providers seeking diagnostic insight into inherited disease risk.

9Health & Wellness Test
CategoryWellness / lifestyle genetic test
Description

Wellness-focused genetic test analyzing 80+ genes for personalized insights into nutrition, metabolism, fitness, skin health, allergies, detoxification, and sleep patterns. Priced at ₦450,000 direct-to-consumer.

10Pharmacogenomics Test
CategoryPharmacogenomics / drug response testing
Description

Pharmacogenomic test revealing how an individual's genes affect response to drugs across cardiology, psychiatry, oncology, and pain management. Covers CYP2D6, CYP2C19, DPYD, TPMT, and other pharmacogenetic markers. Pricing not publicly disclosed.

11Hereditary Breast and Ovarian Cancer Test
CategoryHereditary cancer diagnostic test
Description

Focused hereditary cancer panel analyzing BRCA1/2, PALB2, CHEK2, and other genes (50 genes total) for inherited breast and ovarian cancer risk. Pricing not publicly disclosed.

12Hereditary Prostate Cancer Test
CategoryHereditary cancer diagnostic test
Description

Hereditary cancer panel screening 23 genes including BRCA1/2 and HOXB13 for inherited prostate cancer risk, with relevance to African populations. Pricing not publicly disclosed.

13Hereditary Pancreatic Cancer Test
CategoryHereditary cancer diagnostic test
Description

Hereditary cancer test analyzing 32 genes including BRCA1/2, PALB2, CDKN2A, and STK11 for inherited pancreatic cancer risk. Pricing not publicly disclosed.

14Hereditary Colorectal Cancer Test
CategoryHereditary cancer diagnostic test
Description

Hereditary cancer panel screening 44 genes linked to Lynch syndrome, familial adenomatous polyposis (FAP), and other hereditary colorectal cancers. Pricing not publicly disclosed.

15Comprehensive Hereditary Cancer Test
CategoryHereditary cancer diagnostic test
Description

One of the most comprehensive hereditary cancer panels in Africa, covering ~300 genes across 13+ organ systems including breast, ovarian, colorectal, prostate, pancreatic, gastric, melanoma, and endocrine tumors. Priced at ₦750,000 direct-to-consumer and ₦712,500 for providers.

16OncoMap130
CategoryOncology somatic tumor profiling
Description

Comprehensive 130-gene solid tumor profiling panel detecting clinically actionable mutations across lung, breast, colorectal, prostate, and ovarian cancers. Includes pharmacogenetic markers (DPYD, TPMT, NUDT15) for chemotherapy toxicity prevention and complete MSI marker coverage for immunotherapy decisions. Supports targeted therapy selection and clinical trial enrollment.

17OncoMap90
CategoryOncology somatic tumor profiling
Description

90-gene panel specifically designed for myeloid malignancies including AML (acute myeloid leukemia), MDS (myelodysplastic syndromes), and MPN (myeloproliferative neoplasms). Provides critical insight into prognosis, targeted therapy selection, and clinical trial eligibility. Priced at ₦900,000 direct-to-consumer and ₦855,000 for providers.

18Complete Genetic Health Package
CategoryBundled genetic testing package
Description

Premium bundled package combining the Hereditary Conditions Test, Comprehensive Hereditary Cancer Test, and Health & Wellness Test in a single offering with cost savings of ₦450,000 versus purchasing separately. Priced at ₦1,500,000 direct-to-consumer and ₦1,425,000 for providers.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1National Institute for Cancer Research and Treatment (NICRAT) Nigeria
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-01
Description

Collaborative partnership for the Cancer Genome Nigeria Study - the first systematic genomic profiling of Nigerian cancers. The study analyzed 442 variants across 41 genes in 50 tumors, revealing both global drivers and distinctive enrichments (ALK, FGFR4) specific to Nigerian populations. 80% of variants classified as clinically significant. Joint whitepaper authored and released October 2025 outlining policy recommendations for integrating precision oncology into Nigeria's healthcare system.

direct.syndicate.bio
2Precision54 Network Collaborators
Strategic tierMinorTypeOthers
Description

The company's website displays logos of 'Organizations supporting our mission' with 12 collaborator images, but specific partner names are not individually identified. These appear to be healthcare providers, research institutions, and industry partners participating in the Precision54 network.

syndicate.bio
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Nigerian genomics startup founded by the same founder (Abasi Ene-Obong). The most direct comparable as a prior African-focused genomics venture with similar precision-medicine mission; serves as both a precedent and a potential cautionary benchmark.

TypeDirect peer
Description

Population genomics company offering hereditary cancer screening, pharmacogenomics, and DTC testing with strong pharma partnerships. Closely comparable business model combining clinical-grade panels, DTC access, and enterprise pharma data programs.

TypeDirect peer
Description

DNA testing platform combining clinical genomics, health systems, and research partnerships. Comparable in operating a sequencing platform that serves both consumers and pharma/research customers through a network model.

TypeBroad incumbent
Description

Large-scale genetic testing company with reproductive health (NIPT) and oncology offerings. Overlaps directly with Syndicate Bio's NIPT and OncoMap panels; significantly larger with established US clinical footprint.

TypeBroad incumbent
Description

Established leader in hereditary cancer testing (BRCA1/2, comprehensive panels). Direct overlap with Syndicate Bio's hereditary cancer panel strategy but with vastly larger scale and pharma partnerships.

TypeBroad incumbent
Description

Comprehensive genetic testing company spanning hereditary cancer, reproductive, and rare disease. Comparable breadth of menu and provider-facing clinical reports; competes on scale and reimbursement infrastructure.

TypeBroad incumbent
Description

Somatic cancer genomic profiling leader (Roche subsidiary). Direct overlap with Syndicate Bio's OncoMap130/OncoMap90 panels and pharma data partnership model; vastly larger reference database and pharma relationships.

TypeDirect peer
Description

DTC genetic testing leader with health and ancestry reports. Comparable consumer-facing genetic testing model and brand-led marketing, though focused on US/European populations without African-specific panels.

TypeRegional player
Description

Pan-African clinical laboratory network headquartered in South Africa. Comparable clinical lab infrastructure across Africa but broader routine diagnostics focus rather than specialty genomics.

TypeEmerging player
Description

Genomics platform company leveraging new sequencing technologies with disease detection applications. Comparable emerging-stage genomics platform with pharma partnerships and multi-omics ambitions.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Syndicate Bio

Genetic Testing & Genomic Diagnosticssyndicate.bio

Syndicate Bio is a genomics and precision medicine company that sells clinical-grade genetic testing directly to Nigerian consumers and healthcare providers through its Direct platform, and operates the Precision54 Clinical Hub to connect pharma and biotech partners to African clinical research sites.

What Syndicate Bio does

Syndicate Bio is a privately held genomics and precision medicine company founded in 2023 by Abasi Ene-Obong (formerly of 54gene) and operating dual hubs in Newark, Delaware, USA and Lagos, Nigeria. The company operates two go-to-market platforms: Direct by Syndicate Bio, a direct-to-consumer health portal offering an 18-product genetic testing catalog including non-invasive prenatal testing (NIPT), hereditary cancer panels (23-gene to ~300-gene tiers), the OncoMap130 solid tumor and OncoMap90 myeloid oncology panels, pharmacogenomics, and wellness testing, all priced in Nigerian Naira (₦350,000–₦1,500,000); and the Precision54 Clinical Hub, a B2B platform connecting pharmaceutical and biotechnology companies to pre-qualified clinical research sites across Africa for collaborative precision medicine studies.

Underlying technology is next-generation sequencing (NGS) combined with AI/ML analytics applied across multi-omics disciplines (genomics, proteomics, metabolomics, bioinformatics). Syndicate Bio operates an ISO 9001:2015- and ISO 15189:2022-compliant laboratory and positions itself around the genetic diversity of African populations, including Africa-prevalent conditions such as sickle cell disease, thalassemia, G6PD deficiency, and hereditary amyloidosis. Revenue is generated through one-time per-test fees from consumers and healthcare providers (with provider pricing approximately 5% below DTC rates) plus professional-services revenue from pharma/biotech research collaborations. The company's October 2025 Cancer Genome Nigeria Study with NICRAT — analyzing 442 variants across 41 genes in 50 tumors and identifying distinctive ALK and FGFR4 enrichments — establishes its foundational proprietary dataset.

Syndicate Bio firmographics

Firmographics
Name
Syndicate Bio
Legal name
Syndicate Bio
Website
https://syndicate.bio
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
11–50 employees
Short description
Syndicate Bio is a genomics and precision medicine company that sells clinical-grade genetic testing directly to Nigerian consumers and healthcare providers through its Direct platform, and operates the Precision54 Clinical Hub to connect pharma and biotech partners to African clinical research sites.
Ownership category
akta.pro rank

Syndicate Bio industry classification

Industry
Product category
Genetic Testing & Genomic Diagnostics
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAFAMAH
Genetic & Prenatal Testing Laboratories
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)

Keywords

  • Genetic testing services
  • Clinical genomics platform
  • Precision medicine solutions
  • Cancer genomic profiling
  • Non-invasive prenatal testing

Where Syndicate Bio is headquartered

Location

Headquarters

HQ city
Lagos
HQ country
Nigeria
HQ region
Africa

Offices2 records

Markets served

Syndicate Bio business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Technology or R&D

Revenue model

  1. Direct-to-Consumer Genetic Testing: Individual consumers purchase genomic tests directly through the Direct platform, including NIPT, hereditary cancer panels, pharmacogenomics, and wellness tests. Tests are priced at various tiers with provider and consumer pricing options.
  2. Healthcare Provider Testing Services: Oncologists, hospitals, and clinics order tests for patients, receiving clinical-grade reports with actionable guidance. Pricing differs from direct consumer rates (approximately 5% lower for providers).
  3. Pharma/Biotech Research Partnerships: Collaborative data projects, clinical studies, and sponsored testing for pharmaceutical and biotech companies through the Precision54 Clinical Hub. Enables pharma partners to access African genetic diversity for drug discovery and development.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goNIPT Gender - Basic gender determination test
Unit PricingPay-as-you-goNIPT Basic - Screens for Trisomy 21, 18, 13
Unit PricingPay-as-you-goNIPT Standard - Adds sex chromosome aneuploidies and 19 autosomal aneuploidies
Unit PricingPay-as-you-goNIPT Plus - Most comprehensive NIPT with 60+ microdeletion syndromes
Unit PricingPay-as-you-goHereditary Conditions Test - 90+ genes for inherited conditions
Unit PricingPay-as-you-goHealth & Wellness Test - 80+ wellness-related genes
Unit PricingPay-as-you-goPharmacogenomics Test - Drug response genes
Unit PricingPay-as-you-goHereditary Breast & Ovarian Cancer Test - 50 genes
Unit PricingPay-as-you-goHereditary Prostate Cancer Test - 23 genes
Unit PricingPay-as-you-goHereditary Pancreatic Cancer Test - 32 genes
Unit PricingPay-as-you-goHereditary Colorectal Cancer Test - 44 genes
Unit PricingPay-as-you-goOncoMap130 - 130 genes for solid tumors with pharmacogenetics
Unit PricingPay-as-you-goOncoMap90 - 90 genes for myeloid malignancies
Unit PricingPay-as-you-goComprehensive Hereditary Cancer Test - ~300 genes
Unit Pricing—Complete Genetic Health Package - All three flagship panels combined

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Syndicate Bio product offering

Product offering

Core offering

Syndicate Bio sells clinical-grade genetic testing services — including NIPT, hereditary cancer panels, hereditary conditions tests, pharmacogenomics, wellness tests, and oncology tumor profiling (OncoMap130, OncoMap90) — through its Direct by Syndicate Bio consumer portal and through healthcare provider channels. The company also operates the Precision54 Clinical Hub, a B2B research network platform enabling pharmaceutical and biotech companies to run precision medicine studies and access pre-qualified clinical sites across Africa. All products are anchored in African-population genomic data and ISO-certified laboratory quality standards.

Product overview

Syndicate Bio is a global genomics and precision medicine company offering a comprehensive portfolio of genetic testing products through its Direct by Syndicate Bio portal. The core offering includes clinical genetic tests organized into three flagship categories: Hereditary Conditions Tests (90+ genes for blood, heart, neurological, metabolic conditions), Hereditary Cancer Tests (ranging from focused 23-50 gene panels to comprehensive ~300 gene panels), and Health & Wellness Tests (80+ genes). The company also provides specialized oncology solutions including OncoMap130 (solid tumor profiling) and OncoMap90 (myeloid cancer panel), as well as Non-Invasive Prenatal Testing (NIPT) with four tiers from gender-only to Plus with microdeletion screening. The Precision54 Clinical Hub provides pharmaceutical and biotech partners with access to pre-qualified research sites across Africa. All tests are designed with African genetic diversity in mind, including variants common in Nigerian and broader African populations.

Differentiator

Problem solved

Functional benefit

Brands

  • Precision54: Clinical hub and network for accessing cutting-edge research and pre-qualified clinical trial sites in Africa.
  • Direct by Syndicate Bio

Products and services

  • Direct by Syndicate Bio Personal health portal that allows individuals to order genetic tests online, view results securely, and access optional genetic counseling and the Second Opinion Service. Targets health-conscious consumers in Africa seeking direct access to clinical-grade genomic testing.
  • Precision54 Clinical Hub B2B research network platform connecting pharmaceutical and biotechnology companies with pre-qualified clinical research sites across Africa. Enables collaborative clinical studies, sponsored testing, and data projects with faster study startup times, giving pharma partners access to African genetic diversity for drug discovery and precision medicine research.
  • NIPT (Non-Invasive Prenatal Test) Non-invasive prenatal test analyzing fetal DNA from maternal blood to screen for chromosomal conditions including Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18), and Patau syndrome (Trisomy 13). Performed from 10 weeks of pregnancy with no miscarriage risk. Targets expectant parents seeking safe prenatal screening.
  • NIPT Gender Entry-level non-invasive prenatal test providing accurate fetal gender determination and fetal fraction estimation from 10 weeks of pregnancy. Priced at ₦350,010 direct-to-consumer.
  • NIPT Basic Basic NIPT screening for Trisomy 21 (Down syndrome), Trisomy 18 (Edwards syndrome), and Trisomy 13 (Patau syndrome) with gender determination from 10 weeks of pregnancy. Priced at ₦350,000 direct-to-consumer.
  • NIPT Standard Comprehensive NIPT screening expanding coverage beyond NIPT Basic to include 6 sex chromosome aneuploidies, 19 additional autosomal aneuploidies, and fetal fraction estimation. Priced at ₦500,000 direct-to-consumer.
  • NIPT Plus Most comprehensive NIPT option covering all Standard features plus 60+ microdeletion and duplication syndromes including Jacobsen syndrome and DiGeorge syndrome. Priced at ₦800,000 direct-to-consumer.
  • Hereditary Conditions Test Clinical-grade genetic test screening 90+ genes for inherited conditions including sickle cell disease, G6PD deficiency, thalassemia, hereditary amyloidosis, and other blood, heart, nerve, immune, metabolic, and eye conditions. Targets individuals and providers seeking diagnostic insight into inherited disease risk.
  • Health & Wellness Test Wellness-focused genetic test analyzing 80+ genes for personalized insights into nutrition, metabolism, fitness, skin health, allergies, detoxification, and sleep patterns. Priced at ₦450,000 direct-to-consumer.
  • Pharmacogenomics Test Pharmacogenomic test revealing how an individual's genes affect response to drugs across cardiology, psychiatry, oncology, and pain management. Covers CYP2D6, CYP2C19, DPYD, TPMT, and other pharmacogenetic markers. Pricing not publicly disclosed.
  • Hereditary Breast and Ovarian Cancer Test Focused hereditary cancer panel analyzing BRCA1/2, PALB2, CHEK2, and other genes (50 genes total) for inherited breast and ovarian cancer risk. Pricing not publicly disclosed.
  • Hereditary Prostate Cancer Test Hereditary cancer panel screening 23 genes including BRCA1/2 and HOXB13 for inherited prostate cancer risk, with relevance to African populations. Pricing not publicly disclosed.
  • Hereditary Pancreatic Cancer Test Hereditary cancer test analyzing 32 genes including BRCA1/2, PALB2, CDKN2A, and STK11 for inherited pancreatic cancer risk. Pricing not publicly disclosed.
  • Hereditary Colorectal Cancer Test Hereditary cancer panel screening 44 genes linked to Lynch syndrome, familial adenomatous polyposis (FAP), and other hereditary colorectal cancers. Pricing not publicly disclosed.
  • Comprehensive Hereditary Cancer Test One of the most comprehensive hereditary cancer panels in Africa, covering ~300 genes across 13+ organ systems including breast, ovarian, colorectal, prostate, pancreatic, gastric, melanoma, and endocrine tumors. Priced at ₦750,000 direct-to-consumer and ₦712,500 for providers.
  • OncoMap130 Comprehensive 130-gene solid tumor profiling panel detecting clinically actionable mutations across lung, breast, colorectal, prostate, and ovarian cancers. Includes pharmacogenetic markers (DPYD, TPMT, NUDT15) for chemotherapy toxicity prevention and complete MSI marker coverage for immunotherapy decisions. Supports targeted therapy selection and clinical trial enrollment.
  • OncoMap90 90-gene panel specifically designed for myeloid malignancies including AML (acute myeloid leukemia), MDS (myelodysplastic syndromes), and MPN (myeloproliferative neoplasms). Provides critical insight into prognosis, targeted therapy selection, and clinical trial eligibility. Priced at ₦900,000 direct-to-consumer and ₦855,000 for providers.
  • Complete Genetic Health Package Premium bundled package combining the Hereditary Conditions Test, Comprehensive Hereditary Cancer Test, and Health & Wellness Test in a single offering with cost savings of ₦450,000 versus purchasing separately. Priced at ₦1,500,000 direct-to-consumer and ₦1,425,000 for providers.

Quantifiable outcome

  • 442 variants analyzed across 50 tumors and 41 genes in first national Nigerian cancer genomics study
  • +4 more outcomes

Companies that use Syndicate Bio

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles1 record

Syndicate Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

Syndicate Bio partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and minor.

  • National Institute for Cancer Research and Treatment (NICRAT) NigeriacoreStrategic or Co-development Partner · 1 October 2025Collaborative partnership for the Cancer Genome Nigeria Study - the first systematic genomic profiling of Nigerian cancers. The study analyzed 442 variants across 41 genes in 50 tumors, revealing both global drivers and distinctive enrichments (ALK, FGFR4) specific to Nigerian populations. 80% of variants classified as clinically significant. Joint whitepaper authored and released October 2025 outlining policy recommendations for integrating precision oncology into Nigeria's healthcare system.
  • Precision54 Network CollaboratorsminorOthersThe company's website displays logos of 'Organizations supporting our mission' with 12 collaborator images, but specific partner names are not individually identified. These appear to be healthcare providers, research institutions, and industry partners participating in the Precision54 network.

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Syndicate Bio competitors and assessment

Company assessment

Direct peers

  • 54gene: Nigerian genomics startup founded by the same founder (Abasi Ene-Obong). The most direct comparable as a prior African-focused genomics venture with similar precision-medicine mission; serves as both a precedent and a potential cautionary benchmark.
  • Color Health: Population genomics company offering hereditary cancer screening, pharmacogenomics, and DTC testing with strong pharma partnerships. Closely comparable business model combining clinical-grade panels, DTC access, and enterprise pharma data programs.
  • Helix: DNA testing platform combining clinical genomics, health systems, and research partnerships. Comparable in operating a sequencing platform that serves both consumers and pharma/research customers through a network model.
  • 23andMe: DTC genetic testing leader with health and ancestry reports. Comparable consumer-facing genetic testing model and brand-led marketing, though focused on US/European populations without African-specific panels.

Broad incumbents

  • Natera: Large-scale genetic testing company with reproductive health (NIPT) and oncology offerings. Overlaps directly with Syndicate Bio's NIPT and OncoMap panels; significantly larger with established US clinical footprint.
  • Myriad Genetics: Established leader in hereditary cancer testing (BRCA1/2, comprehensive panels). Direct overlap with Syndicate Bio's hereditary cancer panel strategy but with vastly larger scale and pharma partnerships.
  • Invitae: Comprehensive genetic testing company spanning hereditary cancer, reproductive, and rare disease. Comparable breadth of menu and provider-facing clinical reports; competes on scale and reimbursement infrastructure.
  • Foundation Medicine: Somatic cancer genomic profiling leader (Roche subsidiary). Direct overlap with Syndicate Bio's OncoMap130/OncoMap90 panels and pharma data partnership model; vastly larger reference database and pharma relationships.

Regional players

  • Lancet Laboratories: Pan-African clinical laboratory network headquartered in South Africa. Comparable clinical lab infrastructure across Africa but broader routine diagnostics focus rather than specialty genomics.

Emerging players

  • Mammoth Biosciences: Genomics platform company leveraging new sequencing technologies with disease detection applications. Comparable emerging-stage genomics platform with pharma partnerships and multi-omics ambitions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Syndicate Bio social profiles

Digital presence

Syndicate Bio compliance and trust

Trust signal

Compliance3 records

Syndicate Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Syndicate Bio leadership team

Management profile

Number of profiles

Profiles5 records

Syndicate Bio funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Syndicate Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Syndicate Bio

What does Syndicate Bio do?

Syndicate Bio sells clinical-grade genetic testing services — including NIPT, hereditary cancer panels, hereditary conditions tests, pharmacogenomics, wellness tests, and oncology tumor profiling (OncoMap130, OncoMap90) — through its Direct by Syndicate Bio consumer portal and through healthcare provider channels. The company also operates the Precision54 Clinical Hub, a B2B research network platform enabling pharmaceutical and biotech companies to run precision medicine studies and access pre-qualified clinical sites across Africa. All products are anchored in African-population genomic data and ISO-certified laboratory quality standards.

Is Syndicate Bio a public or private company?

Syndicate Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Syndicate Bio founded?

Syndicate Bio was founded in 2023. It employs 11 to 50 people.

Where is Syndicate Bio based?

Syndicate Bio is headquartered in Lagos, Nigeria, in the Africa region.

How does Syndicate Bio make money?

Three revenue lines are on record. Direct-to-Consumer Genetic Testing is the primary driver. The others are healthcare Provider Testing Services and pharma/Biotech Research Partnerships.

Who are Syndicate Bio's main competitors?

Direct peers on record are 54gene, Color Health, Helix and 23andMe. Broad incumbents are Natera, Myriad Genetics, Invitae and Foundation Medicine. Lancet Laboratories is listed as a regional player. Mammoth Biosciences is listed as an emerging player.

Does Syndicate Bio have an API?

No public API is recorded for Syndicate Bio.

What industry is Syndicate Bio in?

Syndicate Bio's product category is Genetic Testing & Genomic Diagnostics. Its primary akta.pro industry code is HLAFAMAE, Molecular Diagnostics & Genomics Laboratories, with a secondary code of HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TechCabalFive African founders who staged major comebacks in 2025African tech venture funding has recovered to over $3 billion in 2025, a 36% jump from $2.2 billion, with capital now flowing in larger, more deliberate tranches focused on proven business models rather than early-stage experiments. The article profiles five African founders who returned after startup failures—Meshack Alloys (Sendy to TABB), Tesh Mbaabu (MarketForce to Cloud9), Abasi Ene-Obong (54gene to Syndicate Bio), William McCarren (Zumi to FARO), and Alexandria Procter (DigsConnect to Pharos of Alexandria Ventures)—illustrating how failure is being reframed as a stress test that provides granular market knowledge. This shift reflects a broader trend where investors prioritize operational discipline, capital efficiency, and revenue-generating businesses over speculative expansion, with local banks increasingly participating through structured debt.TechMoranFeyisayo “Sayo” Eweje: Engineering The Future of Gene Therapy : TechMoranDr. Feyisayo "Sayo" Eweje, a Nigerian-American scientist at Harvard's Wyss Institute, is developing ENTER, a self-assembling human protein nanoparticle system designed to deliver gene editors like CRISPR into cells more efficiently and safely than current methods, potentially eliminating the need for chemotherapy in treating inherited disorders like sickle cell disease and cystic fibrosis. He co-founded Procure Bio to commercialize this delivery technology for in-vivo gene editing, focusing on cystic fibrosis, lung delivery, and inherited blood disorders. Separately, Eweje founded Syndicate Bio, which operates a genetic testing and precision medicine service across Africa through its Direct platform, with a sequencing laboratory in Lagos serving Nigeria's population.FinancialContent Business PageCORRECTION: Direct by Syndicate Bio Launches to Power AI-Enabled Precision Medicine in NigeriaSyndicate Bio launched Direct by Syndicate Bio, an AI-enabled genomic and multi-omics testing service, with a new sequencing laboratory in Lagos. The portfolio includes hereditary cancer, somatic oncology, NIPT, pharmacogenomics, and wellness testing, and a joint tumor board with Roswell Park will drive clinical adoption.Techish KenyaSyndicate Bio Launches AI Genomics Platform in Nigeria to Power Precision Medicine for AfricaSyndicate Bio launched Direct by Syndicate Bio, an AI-powered genetic testing service, in Nigeria with a new Lagos sequencing laboratory. The platform offers hereditary cancer panels, prenatal testing, and pharmacogenomics, aiming to generate genomic data from Africa's diverse population. It also established a precision medicine network with partners like Roswell Park and Lakeshore Cancer Center.TechCabalWhy Syndicate Bio wants to decode African DNA to fight cancerSyndicate Bio launched a sequencing laboratory in Lagos to provide local genomic testing, addressing Africa's less than 3% global sequencing share. Its Direct service analyzes over 300 genes for cancer and hereditary disorders, with plans to expand to kinship testing and newborn screening.NubiacapitalNubia Capital Invests in Syndicate Bio to Advance Precision Medicine and Inclusive Genomic Research in AfricaNubia Capital invested in Syndicate Bio, a precision medicine company developing genomic datasets from African populations. The company has discovered over 75 million novel genetic variants and partners with governments and research institutions. The investment aims to address the lack of African genomic data, which represents less than 2.5% of global genomic data.NairametricsNigerian biotech startup becomes first African lab to offer liquid biopsy to advance cancer diagnosisNigerian biotech startup Syndicate Bio partnered with SophiaGenetics to become Africa's first lab offering liquid biopsy and genomic profiling services. The initiative addresses 1.1 million new cancer cases annually in Africa, with mortality projected to reach one million by 2030. The lab aims to enable precision medicine across the continent.DisruptafricaNigerian biotech startup Syndicate Bio to implement new liquid biopsy offering to advance cancer diagnosticsNigerian biotech startup Syndicate Bio partnered with SOPHiA GENETICS to become the first African lab to offer comprehensive genomic profiling and liquid biopsy. The September launch, led by Dr Abasi Ene-Obong, aims to advance precision medicine across Africa, with a November partnership with NICRAT for the Cancer Genome Nigeria project.PR NewswireSOPHiA GENETICS Announces Syndicate Bio as First Liquid Biopsy Customer in AfricaSOPHiA GENETICS announced that Nigeria-based Syndicate Bio has signed on to implement MSK-ACCESS® powered with SOPHiA DDM™, making it the first lab in Africa to adopt comprehensive genomic profiling and liquid biopsy technology. The implementation aims to address the needs of approximately 1 million new cancer patients annually in Africa, where such testing options have not been widely available. This collaboration, which also involves Memorial Sloan Kettering Cancer Center, seeks to advance health equity by enabling precision medicine and non-invasive cancer analysis across the continent.